Finasteride and Hair Transplantation: Efficacy, Side Effects and Scientific Evidence

Short answer: By reducing dihydrotestosterone (DHT) formation, finasteride can slow follicular miniaturisation in male androgenetic alopecia. Some patients gain hair count and visible coverage. It does not replace transplantation and may be considered particularly to preserve existing, nontransplanted hair. Possible sexual and mood-related adverse effects require an individual medical assessment. [1][2][3]

This article provides information, not a personal prescription or treatment instructions. Treatment decisions require a diagnosis, a clinician and the current product information.

What is finasteride and how does it work?

Genetically susceptible follicles progressively miniaturise in androgenetic alopecia; terminal hairs can become finer and their growth phase shorter. Type II 5-alpha-reductase is one enzyme that converts testosterone into the more potent androgen DHT. Finasteride inhibits this enzyme and reduces DHT production. It aims to reduce hormonal effects on existing follicles; it does not create new follicles or remove genetic susceptibility. [2][3]

Lower DHT does not produce the same response in everyone. Duration of hair loss, miniaturisation, accompanying conditions and adherence matter. A single blood DHT measurement cannot predict an individual's hair growth with certainty.

Who may use it? Age and patient selection

According to the relevant product information, oral finasteride 1 mg is a prescription treatment for androgenetic alopecia in adult men. Evidence does not support routine use under 18, and efficacy data in older age groups are more limited. Telogen effluvium, alopecia areata, scarring alopecia and systemic conditions should be distinguished from androgenetic alopecia. Examination and, when appropriate, trichoscopy are important. [2][3]

Results in men cannot simply be applied to women. Finasteride must not be used during pregnancy because of fetal risk. Official precautions also apply to handling broken or crushed tablets during pregnancy or when pregnancy is possible. [2]

What is the difference between 1 mg and 5 mg?

The standard oral dose studied for male pattern hair loss is 1 mg daily. The 5 mg preparation is primarily used for benign prostatic enlargement. A higher dose should not automatically be assumed to work better for hair. The clinician must consider the product's authorisation, other medicines and individual risks. [2]

How effective is it? What do the studies show?

A 2010 systematic review included 12 randomised controlled trials and 3,927 men. The probability of patients reporting improved hair appearance was higher with finasteride than placebo: short-term relative risk 1.81 (95% confidence interval 1.42–2.32) and long-term relative risk 1.71 (1.15–2.53). These ratios do not mean an individual will grow 81% more hair. They compare the probability of reporting improvement between groups. [1]

The between-group difference in percentage change from baseline hair count was 9.42 percentage points short term and 24.3 percentage points long term. Short term meant ≤12 months and long term ≥24 months. These measures do not describe the same percentage of new hair appearing over the entire scalp. [1]

A response may be noticed after several months. Meaningful assessment commonly uses standardised photographs and suitable measurements at 6–12 months. Gains can diminish after treatment is stopped. [2][3]

How common are sexual adverse effects?

The official 1 mg product information reports the following first-year controlled-trial results. [2]

These figures describe particular trial conditions, not an exact personal risk prediction. The systematic review found a relative risk of erectile dysfunction of 2.22 (95% CI 1.03–4.78). [1] Some adverse effects resolve after stopping treatment or while continuing it. However, postmarketing reports include sexual problems persisting after discontinuation. Their frequency and causation in an individual remain uncertain; persistence should neither be dismissed nor presented as inevitable. [2]

Depression and suicidal thoughts: the 2025 EMA update

After its 2025 review, the European Medicines Agency confirmed suicidal thoughts as an adverse effect of oral finasteride 1 mg and 5 mg tablets, with unknown frequency. Unknown frequency means that available data do not permit a reliable percentage. Users of 1 mg tablets who develop mood changes should stop treatment and seek medical advice. Suicidal thoughts require urgent medical assessment. [4]

This warning does not mean everyone develops a severe psychiatric reaction. History of depression, current mood symptoms and concerns about sexual effects should be discussed before treatment. EMA also concluded that benefits continue to outweigh risks in approved indications with appropriate risk-minimisation measures. [4]

The 11 May 2026 MHRA update likewise emphasises discussing and monitoring psychiatric and sexual effects. Sexual dysfunction has also been reported without mood changes, and some symptoms may persist after stopping treatment. Spontaneous reports alone cannot provide a reliable incidence percentage. [6]

Fertility, semen and PSA

Reduced ejaculate volume can occur, and semen parameters may be affected in some patients. People planning conception or undergoing an infertility assessment should discuss this with their clinician. Finasteride can also lower PSA; its use must be disclosed when prostate screening or PSA results are assessed. [2]

Is topical finasteride safer?

Topical formulations aim to reduce systemic exposure; this does not mean zero systemic absorption. In a 24-week phase III randomised trial published in 2022, 458 men were randomised and 323 completed the study. Completion needs to be considered when interpreting the findings. The change in target-area hair count was +20.2 with topical finasteride versus +6.7 with placebo (p<0.001). Serum DHT declined 34.5% in the topical group and 55.6% in the oral group. [5]

These results concern the particular 0.25% spray studied. They cannot be generalised to every compounded preparation or concentration. Follow-up was limited for assessing long-term risks, and authorisation differs between countries.

Why consider it before or after a hair transplant?

Transplanted hair and existing, nontransplanted hair need separate consideration. Miniaturisation may continue in existing hair susceptible to androgenetic alopecia. For suitable patients, finasteride may therefore support preservation of that hair and the longer-term appearance. It does not guarantee graft anchoring, and it is not compulsory for every transplant patient.

A double-blind, placebo-controlled trial in 79 men studied finasteride from 4 weeks before to 48 weeks after transplantation. Hair surrounding the transplant and overall appearance improved. This does not establish survival of every graft or a universal requirement to use the medicine. The study schedule is not personal treatment advice. [7]

In the KSD clinical assessment, diagnosis, donor reserve, miniaturisation, age and long-term hair-loss risk should be considered together. This is a clinical decision framework, not a research finding that finasteride is mandatory for everyone.

How should the evidence be interpreted?

Group averages from the efficacy review cannot predict a specific person's outcome. A target-area hair count in the topical trial is not the same endpoint as new hair over the whole scalp. Few adverse events during short follow-up do not prove zero long-term risk. [1][5]

Absolute rates and relative risks must also be distinguished: the first-year rates for at least one sexual effect were 3.8% and 2.1%, a difference of 1.7 percentage points. Those figures cannot establish the frequency of persistent postmarketing symptoms. Expected benefit, personal priorities and safety monitoring belong in the treatment decision. [2][6]

Frequently asked questions

Can finasteride be used at age 20?

It may be considered in an adult man with a confirmed diagnosis after medical assessment. Age alone is not enough to decide.

Does hair shed after stopping finasteride?

Treatment-related gains may diminish over time. This does not mean everyone experiences abrupt or equally severe shedding.

Does finasteride cause infertility?

Semen parameters may change in some patients; infertility is not an inevitable outcome. Fertility concerns warrant assessment.

Is topical finasteride free of side effects?

No. Systemic exposure is lower in some studies, but risk is not zero.

Can a hair transplant succeed without finasteride?

Yes. Surgical outcomes depend on several factors. The medication decision concerns, in particular, the future loss of existing hair.

Conclusion

Randomised studies support finasteride as an option for male androgenetic alopecia. Sexual and psychiatric safety warnings nevertheless matter. A balanced discussion should explain expected benefit, absolute adverse-effect rates, uncertainties and alternatives. Medical treatment remains an individual part of transplant planning.

References

Sources checked: 26 October 2026. This article does not replace a personal medical assessment.